Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R W ten Kate

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
European Journal of Clinical Investigation|June 1, 1989
The glomerular sieving of pepsinogen A and C in manR W ten Kate, G Pals, J C Res, et al.
AIDS (London, England)|March 14, 2000
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM studyM H Reijers, H M Weigel, A A Hart, et al.
HIV Clinical Trials|November 25, 2005
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES)S H Lowe, A M J Wensing, E A M Hassink, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 27, 1999
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]M H Reijers, G J Weverling, S Jurriaans, et al.
AIDS (London, England)|February 24, 2001
The ADAM study continued: maintenance therapy after 50 weeks of induction therapyM H Reijers, G J Weverling, S Jurriaans, et al.
AIDS (London, England)|August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyR M Hoetelmans, M H Reijers, G J Weverling, et al.
HIV Medicine|December 5, 2014
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE studyH G Sprenger, N Langebeek, P G H Mulder, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
European Journal of Clinical Investigation|June 1, 1989
The glomerular sieving of pepsinogen A and C in manR W ten Kate, G Pals, J C Res, et al.
AIDS (London, England)|March 14, 2000
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM studyM H Reijers, H M Weigel, A A Hart, et al.
HIV Clinical Trials|November 25, 2005
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES)S H Lowe, A M J Wensing, E A M Hassink, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 27, 1999
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]M H Reijers, G J Weverling, S Jurriaans, et al.
AIDS (London, England)|February 24, 2001
The ADAM study continued: maintenance therapy after 50 weeks of induction therapyM H Reijers, G J Weverling, S Jurriaans, et al.
AIDS (London, England)|August 26, 1998
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyR M Hoetelmans, M H Reijers, G J Weverling, et al.
HIV Medicine|December 5, 2014
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE studyH G Sprenger, N Langebeek, P G H Mulder, et al.
Pageof 4